Big Chem aren't interested in R&D projects, they are willing to pay serious coin for products which work and have jumped through hurdles.
Giving away Flavocide and expecting a company to invest millions in testing was never going to be a successful strategy.
Especially when in Virbac's case they already had a product with identical efficacy exhibiting no resistance, and questions at the time remained around scalability, toxicity etc which no longer is the case.
The market has this priced with no future, deals will eventually flow and they will be on Bio-Genes terms.
News and media, page-74
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.859M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38461 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 12495 | 1 |
View Market Depth
| Last trade - 16.12pm 03/12/2024 (20 minute delay) ? |
| BGT (ASX) Chart |
Day chart unavailable
